Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1076273.RAcXHhIYseHLtwvQhf8RxgfsgRoViv-63Rj-AEV6Wzm8k130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1076273.RAcXHhIYseHLtwvQhf8RxgfsgRoViv-63Rj-AEV6Wzm8k130_assertion type Assertion NP1076273.RAcXHhIYseHLtwvQhf8RxgfsgRoViv-63Rj-AEV6Wzm8k130_head.
- NP1076273.RAcXHhIYseHLtwvQhf8RxgfsgRoViv-63Rj-AEV6Wzm8k130_assertion wasGeneratedBy ECO_0000203 NP1076273.RAcXHhIYseHLtwvQhf8RxgfsgRoViv-63Rj-AEV6Wzm8k130_provenance.
- NP1076273.RAcXHhIYseHLtwvQhf8RxgfsgRoViv-63Rj-AEV6Wzm8k130_assertion wasDerivedFrom befree-2016 NP1076273.RAcXHhIYseHLtwvQhf8RxgfsgRoViv-63Rj-AEV6Wzm8k130_provenance.
- NP1076273.RAcXHhIYseHLtwvQhf8RxgfsgRoViv-63Rj-AEV6Wzm8k130_assertion SIO_000772 23658459 NP1076273.RAcXHhIYseHLtwvQhf8RxgfsgRoViv-63Rj-AEV6Wzm8k130_provenance.
- NP1076273.RAcXHhIYseHLtwvQhf8RxgfsgRoViv-63Rj-AEV6Wzm8k130_assertion evidence source_evidence_literature NP1076273.RAcXHhIYseHLtwvQhf8RxgfsgRoViv-63Rj-AEV6Wzm8k130_provenance.
- NP1076273.RAcXHhIYseHLtwvQhf8RxgfsgRoViv-63Rj-AEV6Wzm8k130_assertion description "[When qPCR-identified amplifications in FGFR1, FGFR2, or FGF3 were grouped to define an FGF pathway-amplified breast cancer in HR-positive patients, the mean reduction in target lesions was 21.1% compared with a 12.0% increase in patients who did not present with FGF pathway-amplified breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1076273.RAcXHhIYseHLtwvQhf8RxgfsgRoViv-63Rj-AEV6Wzm8k130_provenance.